Addex Therapeutics Files 6-K with Press Release
Ticker: ADXN · Form: 6-K · Filed: Apr 30, 2025 · CIK: 1574232
Sentiment: neutral
Topics: filing, press-release, registration-statement
TL;DR
Addex Therapeutics dropped a press release on 4/30, check Exhibit 99.1 for deets.
AI Summary
On April 30, 2025, Addex Therapeutics Ltd. issued a press release, attached as Exhibit 99.1 to this Form 6-K filing. This press release is incorporated by reference into their existing registration statements on Form F-3 (Registration No. 333-255089) and Form S-8 (Registration No. 333-255124).
Why It Matters
This filing indicates that Addex Therapeutics has issued new information via a press release, which is now publicly available and incorporated into their SEC filings, potentially impacting investor understanding of the company's current status.
Risk Assessment
Risk Level: low — This filing is primarily procedural, incorporating a press release into existing SEC filings without new financial disclosures or significant operational updates.
Key Players & Entities
- Addex Therapeutics Ltd. (company) — Registrant
- April 30, 2025 (date) — Date of press release and filing
- Exhibit 99.1 (document) — Attached press release
- Form F-3 (document) — Registration statement
- 333-255089 (registration_number) — Form F-3 registration number
- Form S-8 (document) — Registration statement
- 333-255124 (registration_number) — Form S-8 registration number
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report a press release issued by Addex Therapeutics Ltd. on April 30, 2025, and incorporate it by reference into the company's SEC filings.
What specific document is attached as Exhibit 99.1?
Exhibit 99.1 is a press release dated April 30, 2025.
Which registration statements does the press release get incorporated into?
The press release is incorporated into the registration statement on Form F-3 (Registration No. 333-255089) and the registration statement on Form S-8 (Registration No. 333-255124).
What is the filing date and period of report for this 6-K?
The filing date and the period of report are both April 30, 2025.
Where is Addex Therapeutics Ltd. headquartered?
Addex Therapeutics Ltd. is headquartered in Geneva, Switzerland, with its principal executive office located at Chemin des Mines 9, CH-1202 Geneva.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 30, 2025 regarding Addex Therapeutics Ltd. (ADXN).